Aim Methods Data from 19 Italian centers involved in the treatment of metastatic RCC were retrospectively collected. Kaplan-Meier and log-rank test methods were used to evaluate the overall survival (OS). Clinical variables considered were sex, age, concomitant metastasis to other sites, surgical resection of PM-RCC and time to PM-RCC occurrence. A subsequent univariate and backward multivariate Cox regression model was fitted to the data to correct for the effect of covariates. Results 103 patients were enrolled in the analysis; 66 of them were males. Median age was 67 yrs (range 43–85 yrs). PM-RCC were synchronous in only 3 patients (3%). In 56 patients (54%), the pancreas was the only metastatic site, whereas in the other 47 patients lung (57%), lymph nodes (28%) and liver (21%) were the most common concomitant metastatic sites. Median time for PM-RCC occurrence was 9.6 yrs (range 0–24 yrs) after nephrectomy. Surgical resection of PM-RCC was performed in 40 patients (39%) and consisted of total (21%), distal (71%) or central pancreatectomy (8%). Median OS was not reached in patients who underwent surgical resection of PM-RCC and 11.1 yrs in the unresected patients (p < 0.001). At univariate analysis, only the presence of concomitant metastases to other sites (p = 0.008) was significantly associated with a poor prognosis, whereas none of the evaluated variables were independent prognostic factors at multivariate analysis. Conclusions The presence of PM-RCC is associated with long survival, which is surprisingly not associated with surgical resection, time of PM-RCC occurrence and the presence of concomitant metastases to other sites, although these data should be confirmed in a larger population.

Renal metastases to pancreas: do not operate all and always? / Burattini, L; Santoni, M; Porta, C; Sternberg, Cn; Procopio, G; Basso, U; De Giorgi, U; Rizzo, M; Ortega, C; Massari, F; Masini, C; Milella, M; Di Lorenzo, G; Cerbone, L; Conti, A; Buti, S; Partelli, S; Falconi, M; Santini, D; Cascinu, S. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 25:supplement 4(2014), pp. iv287-iv287. [10.1093/annonc/mdu337]

Renal metastases to pancreas: do not operate all and always?

Buti S;
2014-01-01

Abstract

Aim Methods Data from 19 Italian centers involved in the treatment of metastatic RCC were retrospectively collected. Kaplan-Meier and log-rank test methods were used to evaluate the overall survival (OS). Clinical variables considered were sex, age, concomitant metastasis to other sites, surgical resection of PM-RCC and time to PM-RCC occurrence. A subsequent univariate and backward multivariate Cox regression model was fitted to the data to correct for the effect of covariates. Results 103 patients were enrolled in the analysis; 66 of them were males. Median age was 67 yrs (range 43–85 yrs). PM-RCC were synchronous in only 3 patients (3%). In 56 patients (54%), the pancreas was the only metastatic site, whereas in the other 47 patients lung (57%), lymph nodes (28%) and liver (21%) were the most common concomitant metastatic sites. Median time for PM-RCC occurrence was 9.6 yrs (range 0–24 yrs) after nephrectomy. Surgical resection of PM-RCC was performed in 40 patients (39%) and consisted of total (21%), distal (71%) or central pancreatectomy (8%). Median OS was not reached in patients who underwent surgical resection of PM-RCC and 11.1 yrs in the unresected patients (p < 0.001). At univariate analysis, only the presence of concomitant metastases to other sites (p = 0.008) was significantly associated with a poor prognosis, whereas none of the evaluated variables were independent prognostic factors at multivariate analysis. Conclusions The presence of PM-RCC is associated with long survival, which is surprisingly not associated with surgical resection, time of PM-RCC occurrence and the presence of concomitant metastases to other sites, although these data should be confirmed in a larger population.
2014
Renal metastases to pancreas: do not operate all and always? / Burattini, L; Santoni, M; Porta, C; Sternberg, Cn; Procopio, G; Basso, U; De Giorgi, U; Rizzo, M; Ortega, C; Massari, F; Masini, C; Milella, M; Di Lorenzo, G; Cerbone, L; Conti, A; Buti, S; Partelli, S; Falconi, M; Santini, D; Cascinu, S. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 25:supplement 4(2014), pp. iv287-iv287. [10.1093/annonc/mdu337]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2906937
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact